Please login to the form below

Not currently logged in

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

Gilead Sciences

MacroGenics could receive up to $1bn as part of a new deal with Gilead to research antibodies for four undisclosed targets.

Driving the deal's high value is MacroGenics' promising dual-affinity re-targeting (DART) technology, which Gilead will be hoping to harness in its quest to producing antibody-based therapies that can simultaneously target two different antigens.

The technology's promise has already seen MacroGenics sign a number of pharma deals, tying up with the likes of Boehringer Ingelheim and Servier, and the US-based biotech said it expects the first investigational new drug application for a compound developed using DART to be submitted in late 2013.

The latest agreement involves four targets in total, with Gilead to hold exclusive worldwide rights for three of the programmes.

For the remaining programme, Gilead will hold development and commercialisation rights in North America, Europe, Australia and New Zealand, with MacroGenics retaining rights in all other markets, including Japan, China and Russia.

In financial terms, Gilead will fund research activities in all four programmes in addition to a total of up to $30m in license fee payments and up to $85m in pre-clinical milestone payments.

However, MacroGenics said the total value of the deal could top $1bn if all four programmes achieve the relevant clinical, regulatory and commercialisation milestones.

“We are very pleased to enter this collaboration with Gilead, a world-class biopharmaceutical company committed to the development of innovative therapeutics,” said Dr Scott Koenig, president and CEO of MacroGenics.

“As the fourth major collaboration around our DART platform in the past two years, this deal represents the latest validation of our ongoing efforts."

10th January 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...